Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial (COAST)
A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST)
Sponsor: Clinical Trial Center North (CTC North GmbH & Co. KG)
Terminated
Lack of recruitment due to low acceptance of the control arm.
Other terminated trials from Clinical Trial Center North (CTC North GmbH & Co. KG)
More terminations from Clinical Trial Center North (CTC North GmbH & Co. KG)
Other Relapsing-Remitting Multiple Sclerosis trials with similar outcome
Listed as NCT04971005, this PHASE2 trial focuses on Relapsing-Remitting Multiple Sclerosis and remains terminated or withdrawn. Sponsored by Clinical Trial Center North (CTC North GmbH & Co. KG), it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Nov 2021 — Apr 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Trial Center North (CTC North GmbH & Co. KG)
- Neovii Biotech
- Universitätsklinikum Hamburg-Eppendorf
For direct contact, visit the study record on ClinicalTrials.gov .